Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
European Society of Cardiology (ESC) Congress Poster Session Reveals Results From Pre-Clinical Study Using CardioCell's Stem Cells for Chronic Ischemic Cardiomyopathy | ||
By: PR Newswire Association LLC. - 28 Aug 2016 | Back to overview list |
|
ROME, Aug. 28, 2016 /PRNewswire/ -- EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2016 -- Study sponsor CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, announces data from its pre-clinical study "Mesenchymal stem cells grown under chronic hypoxia improve LV function and inhibit adverse remodeling in mice with chronic ischemic cardiomyopathy" at a European Society of Cardiology (ESC) Congress Poster Session. Co-Author Dr. Michael Lipinski, ?Interventional Cardiologist at MedStar Washington Hospital Center, presents the study that was designed in collaboration with Drs. Dror Luger, Research Scientist at Washington Hospital Center and Stephen Epstein, Director, Translational and Vascular Biology Research at MedStar Heart and Vascular Institute, Chair of CardioCell's Scientific Advisory Board and Member of CardioCell's Heart Failure Advisory Board. Pre-clinical results using a murine model prove the validity of the hypothesis that intravenous (IV) injection of CardioCell's ischemia-tolerant mesenchymal stem cells (itMSCs) exert beneficial effects on cardiac function in ischemic cardiomyopathy. The results suggest that excessive inflammation is an important cause of the progressive cardiac dysfunction seen in the control group and that itMSCs exert beneficial cardiac effects — at least, in part — by their systemic anti-inflammatory effects. "I believe this study could have transformational effects on the treatment of heart failure (HF)," says Dr. Stephen Epstein, Director, Translational and Vascular Biology Research at MedStar Heart and Vascular Institute. "HF patients will almost certainly not be cured by a single injection of stem cells. This demonstration that IV administration of itMSCs grown under chronic hypoxia improves cardiac dysfunction in HF suggests that IV itMSC administration will be an effective and safe strategy for providing the repeated treatments that will probably be necessary in patients with ischemic cardiomyopathy." Here is a summary of the methodology and results:
The hypothesis of this study was designed to determine whether systemic effects of IV itMSC delivery improves myocardial function. It was previously thought that large numbers of stem cells must be delivered to the myocardium to exert beneficial effects on the heart. The study results show that IV itMSC injection significantly improves LV function and adverse LV remodeling in mice with chronic ischemic cardiomyopathy. The beneficial effects on LV function were associated with itMSC-induced anti-inflammatory effects. Only CardioCell's chronic HF therapies feature itMSCs, which are exclusively licensed from CardioCell's parent company Stemedica. Unlike MSCs grown under normoxic conditions, Stemedica's bone-marrow-derived, allogeneic itMSCs are grown under hypoxic conditions. In vivo experiments demonstrate cells that are exposed to hypoxic conditions show greater homing and engraftment than cells grown under normoxic conditions. Compared to MSCs manufactured under normal oxygen condition, itMSCs secrete higher levels of growth factors and other important proteins associated with neoangiogenesis and healing. About CardioCell LLC About Stemedica Cell Technologies Inc. All media inquiries: Logo - http://photos.prnewswire.com/prnh/20150309/180568LOGO
SOURCE CardioCell LLC |
||
|
||
Copyright 2016 PR Newswire Association LLC. | Back to overview list |